BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.060
-0.030 (-2.75%)
At close: Apr 28, 2026, 4:00 PM EDT
1.060
0.00 (-0.03%)
After-hours: Apr 28, 2026, 7:49 PM EDT
BioXcel Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for BioXcel Therapeutics stock have an average target of 23, with a low estimate of 4.00 and a high estimate of 66. The average target predicts an increase of 2,069.81% from the current stock price of 1.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +371.70% | Apr 2, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +1,503.77% | Mar 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +466.04% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +843.40% | Sep 15, 2025 |
| Mizuho | Mizuho | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +277.36% | Sep 12, 2025 |
Financial Forecast
Revenue This Year
1.91M
from 642.00K
Increased by 197.82%
Revenue Next Year
19.31M
from 1.91M
Increased by 910.15%
EPS This Year
-3.25
from -5.73
EPS Next Year
-1.98
from -3.25
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3.5M | 32.2M | ||||||
| Avg | 1.9M | 19.3M | ||||||
| Low | 754,600 | 5.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 439.7% | 1,585.9% | ||||||
| Avg | 197.8% | 910.1% | ||||||
| Low | 17.5% | 173.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.46 | -1.18 | ||||||
| Avg | -3.25 | -1.98 | ||||||
| Low | -6.58 | -2.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.